Corticobasal Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Corticobasal Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A11890
Buy Now

The corticobasal degeneration market has been comprehensively analyzed in IMARC's new report titled "Corticobasal Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Corticobasal degeneration (CBD) refers to a rare neurodegenerative disorder characterized by progressive deterioration of specific areas in the brain, leading to a range of debilitating symptoms. The condition primarily affects the cerebral cortex and the basal ganglia, causing a gradual decline in motor functions and cognitive abilities. The symptoms of the ailment are varied and often include a combination of movement difficulties, such as muscle stiffness, tremors, and loss of coordination, resembling parkinsonism. These motor impairments are typically asymmetric, affecting one side of the body more severely than the other. Additionally, individuals suffering from CBD may experience cognitive changes, such as memory deficits, language difficulties, and impaired executive functions like planning and decision-making. Diagnosing this illness can be challenging due to its overlap with other neurodegenerative disorders. A comprehensive clinical evaluation is crucial, considering both motor and cognitive symptoms. Neuroimaging techniques, such as magnetic resonance imaging (MRI), can reveal specific patterns of brain atrophy that are indicative of CBD.

Corticobasal Degeneration Market

The escalating incidences of protein abnormalities involving tau and alpha-synuclein, which can lead to the deterioration of brain cells and subsequent motor and cognitive impairments, are primarily driving the corticobasal degeneration market. In addition to this, the inflating utilization of symptom-relieving interventions, such as dopamine-enhancing medications, cholinesterase inhibitors, and botulinum toxin injections to manage the condition's effects, is also creating a positive outlook for the market. Moreover, the widespread adoption of tailored physical and speech therapies, since they can help in boosting muscle tone, mitigating communication challenges, and ameliorating overall motor functions, is further bolstering the market growth. Apart from this, the rising usage of deep brain stimulation procedures which involve the implantation of electrodes to modulate abnormal brain activity and alleviate some of the debilitating indications, is acting as another significant growth-inducing factor. Additionally, the escalating demand for advanced imaging technologies like PET scans and functional MRI, which offer better insights into neural degeneration, is also augmenting the market growth. Furthermore, the emerging popularity of gene therapy strategies, wherein the manipulation of genetic material is performed to rectify or substitute malfunctioning genes accountable for the disorder, is expected to drive the corticobasal degeneration market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the corticobasal degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for corticobasal degeneration and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the corticobasal degeneration market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the corticobasal degeneration market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the corticobasal degeneration market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

Competitive Landscape

This report also provides a detailed analysis of the current corticobasal degeneration marketed drugs and late-stage pipeline drugs.

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs
 Company Name                   
Fasudil Woolsey Pharmaceuticals


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report

Market Insights

  • How has the corticobasal degeneration market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2033?
  • What was the country-wise size of the corticobasal degeneration market across the seven major markets in 2023 and what will it look like in 2033?
  • What is the growth rate of the corticobasal degeneration market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2017-2033) of corticobasal degeneration across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of corticobasal degeneration by age across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of corticobasal degeneration by gender across the seven major markets?
  • What is the number of prevalent cases (2017-2033) of corticobasal degeneration by type across the seven major markets?
  • How many patients are diagnosed (2017-2033) with corticobasal degeneration across the seven major markets?
  • What is the size of the corticobasal degeneration patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of corticobasal degeneration?
  • What will be the growth rate of patients across the seven major markets?
     

Corticobasal Degeneration: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for corticobasal degeneration drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the corticobasal degeneration market?
  • What are the key regulatory events related to the corticobasal degeneration market?
  • What is the structure of clinical trial landscape by status related to the corticobasal degeneration market?
  • What is the structure of clinical trial landscape by phase related to the corticobasal degeneration market?
  • What is the structure of clinical trial landscape by route of administration related to the corticobasal degeneration market? 

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Corticobasal Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More